Trish and Bryce Belanger on March 3 filed a Zofran lawsuit on behalf of their two minor children who were born in 2009 and 2010, respectively, with a number of birth defects allegedly caused by the generic form of Zofran.
Filed in U.S. District Court for the Eastern District of Louisiana, the parents claim that GlaxoSmithKline (GSK) knew its drug was dangerous for expectant mothers, but continued to market it without adequate warning labels. And it was prescribed off label to treat Trish’s morning sickness: Zofran was only approved by the FDA to fight nausea in chemotherapy patients. (Case number 2:16-cv-01806.)
Also in March of this year, Cicily Lafleur and Justin Thibodeaux filed a lawsuit in the U.S. District Court for the Western District Court of Louisiana, Lafayette Division, with similar claims. Cindy Lafleur took Zofran during the first trimester of her pregnancy to treat morning sickness. Her son, Kaden Lafleur, was born in November 2012 and was allegedly diagnosed with congenital heart defects. Kaden required surgery right after his birth and underwent extensive follow-up treatment, according to court documents.
Of more than 220 lawsuits filed to date, most involve the following birth defects:
• cleft palate, cleft lip
• atrial and ventricular septal defects
• transposition of the greater vessels
• respiratory distress syndrome
• ear deformities, kidney defects
READ MORE ZOFRAN BIRTH DEFECT LEGAL NEWS
Instead, GSK began to market its drug as a “safe” and “effective” treatment to OB/GYNs throughout the United States, and Zofran was prescribed to more than one million women during its first year of marketing it off label. GSK has obviously calculated that more profits can be made keeping the drug on the market and facing lawsuits than withdrawing it. The Department of Justice in 2012 slapped the drug giant with a $3 billion fine for “unlawful promotion and failure to report safety data” of several drugs, including Zofran.